Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + pembrolizumab vs gemcitabine + platinum in untreated HER2-positive urothelial carcinoma
jRCT2061240094Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of disitamab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Pfizer. Primary endpoints: Progression-free survival (PFS) per RECIST v1.1 by BICR and Overall survival (OS). Started Jun 2025; status: active, not recruiting.
02
Drugs
disitamab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2061240094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240094.